Why Pleiotropic Interventions are Needed for Alzheimer's Disease

[1]  J. Trojanowski,et al.  Tau-directed drug discovery for Alzheimer's disease and related tauopathies: A focus on tau assembly inhibitors , 2010, Experimental Neurology.

[2]  G. Cole,et al.  DHA may prevent age-related dementia. , 2010, The Journal of nutrition.

[3]  Winnie S. Liang,et al.  Neuronal gene expression in non-demented individuals with intermediate Alzheimer's Disease neuropathology , 2010, Neurobiology of Aging.

[4]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[5]  G. Maru,et al.  Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. , 2010, Journal of agricultural and food chemistry.

[6]  P. Scheltens,et al.  Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial , 2010, Alzheimer's & Dementia.

[7]  M. O’Banion,et al.  Sustained expression of interleukin-1β in mouse hippocampus impairs spatial memory , 2009, Neuroscience.

[8]  Robert C Green,et al.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.

[9]  Bedda L. Rosario,et al.  Basal Cerebral Metabolism May Modulate the Cognitive Effects of Aβ in Mild Cognitive Impairment: An Example of Brain Reserve , 2009, The Journal of Neuroscience.

[10]  Seiji Nishino,et al.  Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle , 2009, Science.

[11]  G. Johnson,et al.  Involvement of oxidative pathways in cytokine-induced secretory phospholipase A2-IIA in astrocytes , 2009, Neurochemistry International.

[12]  L. Mosconi,et al.  Differences in hippocampal metabolism between amnestic and non-amnestic MCI subjects: automated FDG-PET image analysis. , 2009, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[13]  C. Laiño.  In Follow‐up Analysis of Clinical Trial, NSAIDs Seem to Preserve Cognitive Function in Patients with Healthy Brains , 2009 .

[14]  P. Davies,et al.  Age-Dependent Impairment of Cognitive and Synaptic Function in the htau Mouse Model of Tau Pathology , 2009, The Journal of Neuroscience.

[15]  R. Hamilton,et al.  Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[16]  G. Cole,et al.  Omega-3 fatty acids and dementia. , 2009, Prostaglandins, leukotrienes, and essential fatty acids.

[17]  H. Vinters,et al.  β-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin , 2009, The Journal of Neuroscience.

[18]  G. Casadesus,et al.  Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease , 2009, Free radical research.

[19]  Libin Cui,et al.  Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid , 2009, Proceedings of the National Academy of Sciences.

[20]  E. Teng,et al.  Donepezil delays progression to AD in MCI subjects with depressive symptoms , 2009, Neurology.

[21]  S. Pimplikar,et al.  Reassessing the amyloid cascade hypothesis of Alzheimer's disease. , 2009, The international journal of biochemistry & cell biology.

[22]  O. Shido,et al.  Docosahexaenoic acid promotes neuronal differentiation by regulating basic helix–loop–helix transcription factors and cell cycle in neural stem cells , 2009, Neuroscience.

[23]  P. Pasqualetti,et al.  A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease , 2009, Aging clinical and experimental research.

[24]  T. Kokjohn,et al.  Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. , 2009, CNS & neurological disorders drug targets.

[25]  Xue-jun Li,et al.  Curcumin protects PC12 cells from corticosterone-induced cytotoxicity: possible involvement of the ERK1/2 pathway. , 2009, Basic & clinical pharmacology & toxicology.

[26]  Suzanne Craft,et al.  The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. , 2009, Archives of neurology.

[27]  P. Dederen,et al.  DHA and cholesterol containing diets influence Alzheimer-like pathology, cognition and cerebral vasculature in APPswe/PS1dE9 mice , 2009, Neurobiology of Disease.

[28]  E. Mandelkow,et al.  Development of tau aggregation inhibitors for Alzheimer's disease. , 2009, Angewandte Chemie.

[29]  G. Cole,et al.  GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals , 2009, Neurobiology of Disease.

[30]  J. W. Rudy,et al.  Time course of hippocampal IL-1 β and memory consolidation impairments in aging rats following peripheral infection , 2009, Brain, Behavior, and Immunity.

[31]  I. Grundke‐Iqbal,et al.  Mechanisms of tau-induced neurodegeneration , 2009, Acta Neuropathologica.

[32]  A. Palmeri,et al.  Picomolar Amyloid-β Positively Modulates Synaptic Plasticity and Memory in Hippocampus , 2008, The Journal of Neuroscience.

[33]  S. DeKosky,et al.  Increased 5-Lipoxygenase Immunoreactivity in the Hippocampus of Patients With Alzheimer's Disease , 2008, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[34]  B. Hemmer,et al.  Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. , 2008, Archives of neurology.

[35]  L. Mucke,et al.  Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease , 2008, Nature Neuroscience.

[36]  Edward E Knaus,et al.  Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. , 2008, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[37]  T. Wisniewski,et al.  Amyloid-β immunisation for Alzheimer's disease , 2008, The Lancet Neurology.

[38]  Osman A. B. S. M. Gani,et al.  Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha. , 2008, Journal of molecular graphics & modelling.

[39]  F. Gomez-Pinilla,et al.  Docosahexaenoic acid dietary supplementation enhances the effects of exercise on synaptic plasticity and cognition , 2008, Neuroscience.

[40]  Shih-Yi Huang,et al.  The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: A preliminary randomized double-blind placebo-controlled study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[41]  J. Morris,et al.  Will anti-amyloid therapies work for Alzheimer's disease? , 2008, The Lancet.

[42]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[43]  Takashi Morihara,et al.  Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer's Disease , 2008, Journal of Pharmacology and Experimental Therapeutics.

[44]  R. Green,et al.  Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. , 2008, Archives of neurology.

[45]  Á. Simonyi,et al.  Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons , 2008, Journal of neurochemistry.

[46]  E. Faustman,et al.  Fish intake guidelines: incorporating n-3 fatty acid intake and contaminant exposure in the Korean and Japanese communities. , 2008, The American journal of clinical nutrition.

[47]  S. Hendrix,et al.  Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial , 2008, The Lancet Neurology.

[48]  M. Mattson,et al.  Curcumin Stimulates Proliferation of Embryonic Neural Progenitor Cells and Neurogenesis in the Adult Hippocampus* , 2008, Journal of Biological Chemistry.

[49]  Donald R. Miller,et al.  Protective effects of NSAIDs on the development of Alzheimer disease , 2008, Neurology.

[50]  S. Wassall,et al.  Docosahexaenoic acid domains: the ultimate non-raft membrane domain. , 2008, Chemistry and physics of lipids.

[51]  S. Ogston,et al.  Cod liver oil (n-3 fatty acids) as an non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. , 2008, Rheumatology.

[52]  R. Veerhuis,et al.  Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology. , 2008, Current pharmaceutical design.

[53]  B. Jenkins,et al.  Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice , 2008, Brain Research.

[54]  M. Hill,et al.  A Two-Year Study with Fibrillar β-Amyloid (Aβ) Immunization in Aged Canines: Effects on Cognitive Function and Brain Aβ , 2008, The Journal of Neuroscience.

[55]  T. Wisniewski,et al.  5‐Lipoxygenase gene disruption reduces amyloid‐β pathology in a mouse model of Alzheimer's disease , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[56]  V. Mok,et al.  Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. , 2008, Journal of clinical psychopharmacology.

[57]  E. Mandelkow,et al.  Curcumin‐Derived Pyrazoles and Isoxazoles: Swiss Army Knives or Blunt Tools for Alzheimer's Disease? , 2008, ChemMedChem.

[58]  B. Teter,et al.  Omega-3 Fatty Acid Docosahexaenoic Acid Increases SorLA/LR11, a Sorting Protein with Reduced Expression in Sporadic Alzheimer's Disease (AD): Relevance to AD Prevention , 2007, The Journal of Neuroscience.

[59]  A. Takashima,et al.  Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild‐type human tau , 2007, The EMBO journal.

[60]  A. Delgado-Escueta,et al.  Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivo , 2007, Proceedings of the National Academy of Sciences.

[61]  Fei Liu,et al.  Down‐regulation of cAMP‐dependent protein kinase by over‐activated calpain in Alzheimer disease brain , 2007, Journal of neurochemistry.

[62]  F. Calderon,et al.  Role of RXR in neurite outgrowth induced by docosahexaenoic acid. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[63]  F. Pifferi,et al.  n-3 Fatty acids modulate brain glucose transport in endothelial cells of the blood-brain barrier. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[64]  H. Tanila,et al.  Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD) , 2007, Neurobiology of Disease.

[65]  M. Lynch,et al.  Docosahexaenoic acid-induced changes in phospholipids in cortex of young and aged rats: a lipidomic analysis. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[66]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[67]  B. Hyman,et al.  Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model , 2007, Journal of neurochemistry.

[68]  J. Lucas,et al.  Neuronal apoptosis and reversible motor deficit in dominant‐negative GSK‐3 conditional transgenic mice , 2007, The EMBO journal.

[69]  M. O’Banion,et al.  Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. , 2007, The Journal of clinical investigation.

[70]  W. M. van der Flier,et al.  ASSOCIATION BETWEEN VITAMIN B6 AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM , 2007, Journal of the American Geriatrics Society.

[71]  Patrick L. McGeer,et al.  NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies , 2007, Neurobiology of Aging.

[72]  Frank M LaFerla,et al.  Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid-β and Tau Pathology via a Mechanism Involving Presenilin 1 Levels , 2007, The Journal of Neuroscience.

[73]  S. Innis,et al.  Dietary (n-3) fatty acids and brain development. , 2007, The Journal of nutrition.

[74]  G. Collingridge,et al.  LTP Inhibits LTD in the Hippocampus via Regulation of GSK3β , 2007, Neuron.

[75]  B. Rodrigues,et al.  Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism. , 2007, American journal of physiology. Endocrinology and metabolism.

[76]  Rhoda Au,et al.  Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. , 2006, Archives of neurology.

[77]  Michio Hashimoto,et al.  DOCOSAHEXAENOIC ACID‐INDUCED PROTECTIVE EFFECT AGAINST IMPAIRED LEARNING IN AMYLOID β‐INFUSED RATS IS ASSOCIATED WITH INCREASED SYNAPTOSOMAL MEMBRANE FLUIDITY , 2006, Clinical and experimental pharmacology & physiology.

[78]  G. Cole,et al.  Commentary on “Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery.” Pleiotropic approaches to Alzheimer’s and other diseases of aging , 2006, Alzheimer's & Dementia.

[79]  G. Caughey,et al.  Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. , 2006, The Journal of rheumatology.

[80]  Lars-Olof Wahlund,et al.  Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. , 2006, Archives of neurology.

[81]  J. Trojanowski,et al.  Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery , 2006, Alzheimer's & Dementia.

[82]  J. Hey-Hadavi.  Commentary on “Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery.” Atorvastatin’s effect in Alzheimer’s dementia (LEADe) study , 2006, Alzheimer's & Dementia.

[83]  Eun Kyoung Ryu,et al.  Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. , 2006, Journal of medicinal chemistry.

[84]  H. Tanila,et al.  Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice , 2006, Neurobiology of Disease.

[85]  G. Cole,et al.  Docosahexaenoic Acid Protects from Amyloid and Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2006, Nutrition and health.

[86]  K. Ashe.  S5-03-03 A specific amyloid-β assembly in the brain impairs memory , 2006, Alzheimer's & Dementia.

[87]  S. Kang,et al.  Curcumin-induced histone hypoacetylation enhances caspase-3-dependent glioma cell death and neurogenesis of neural progenitor cells. , 2006, Stem cells and development.

[88]  R. Koch,et al.  Omega-3 fatty acids improve the diagnosis-related clinical outcome* , 2006, Critical care medicine.

[89]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[90]  R. Mrak,et al.  Potential inflammatory biomarkers in Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[91]  E. Mandelkow,et al.  Inducible Expression of Tau Repeat Domain in Cell Models of Tauopathy , 2006, Journal of Biological Chemistry.

[92]  T. Klockgether,et al.  Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[93]  K. Ashe,et al.  Age-Dependent Neurofibrillary Tangle Formation, Neuron Loss, and Memory Impairment in a Mouse Model of Human Tauopathy (P301L) , 2005, The Journal of Neuroscience.

[94]  T. Montine,et al.  Deletion of the Prostaglandin E2 EP2 Receptor Reduces Oxidative Damage and Amyloid Burden in a Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.

[95]  Charles N Serhan,et al.  A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. , 2005, The Journal of clinical investigation.

[96]  Zhiming Wen,et al.  Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[97]  Takashi Morihara,et al.  Dietary n‐3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease , 2005, The European journal of neuroscience.

[98]  P. Scheltens,et al.  LOW VITAMIN B6 LEVELS ARE ASSOCIATED WITH WHITE MATTER LESIONS IN ALZHEIMER'S DISEASE , 2005, Journal of the American Geriatrics Society.

[99]  P. Hof,et al.  Cell-Cycle Reentry and Cell Death in Transgenic Mice Expressing Nonmutant Human Tau Isoforms , 2005, The Journal of Neuroscience.

[100]  B. Teter,et al.  Ibuprofen Suppresses Interleukin-1β Induction of Pro-Amyloidogenic α1-Antichymotrypsin to Ameliorate β-Amyloid (Aβ) Pathology in Alzheimer's Models , 2005, Neuropsychopharmacology.

[101]  Thomas Klockgether,et al.  Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice , 2005 .

[102]  R. Ravid,et al.  Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology , 2005, Journal of neurochemistry.

[103]  Takashi Morihara,et al.  A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model , 2005, The Journal of Neuroscience.

[104]  R. Mrak,et al.  Glia and their cytokines in progression of neurodegeneration , 2005, Neurobiology of Aging.

[105]  Fusheng Yang,et al.  Curcumin Inhibits Formation of Amyloid β Oligomers and Fibrils, Binds Plaques, and Reduces Amyloid in Vivo* , 2005, Journal of Biological Chemistry.

[106]  Chi Li,et al.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[107]  D. Perani,et al.  MCI conversion to dementia and the APOE genotype , 2004, Neurology.

[108]  B. Teter,et al.  Insulin-Degrading Enzyme as a Downstream Target of Insulin Receptor Signaling Cascade: Implications for Alzheimer's Disease Intervention , 2004, The Journal of Neuroscience.

[109]  G. Cole,et al.  NSAID and Antioxidant Prevention of Alzheimer's Disease: Lessons from In Vitro and Animal Models , 2004, Annals of the New York Academy of Sciences.

[110]  J. Trojanowski,et al.  Brain inflammation and oxidative stress in a transgenic mouse model of Alzheimer-like brain amyloidosis , 2004, Journal of Neuroinflammation.

[111]  A. Stoll,et al.  Omega-3 Fatty Acid Treatment and T2 Whole Brain Relaxation Times in Bipolar Disorder , 2004 .

[112]  Takashi Morihara,et al.  Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.

[113]  S. Sang,et al.  Modulation of arachidonic acid metabolism by curcumin and related β-diketone derivatives: effects on cytosolic phospholipase A2, cyclooxygenases and 5-lipoxygenase , 2004 .

[114]  Chung Y. Hsu,et al.  Induction of secretory phospholipase A2 in reactive astrocytes in response to transient focal cerebral ischemia in the rat brain , 2004, Journal of neurochemistry.

[115]  S. Goodman,et al.  Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review , 2004, Neuroepidemiology.

[116]  Patrick L. McGeer,et al.  Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease , 2004, Experimental Neurology.

[117]  Hyoung-Gon Lee,et al.  Challenging the Amyloid Cascade Hypothesis: Senile Plaques and Amyloid‐β as Protective Adaptations to Alzheimer Disease , 2004, Annals of the New York Academy of Sciences.

[118]  B. Zipser,et al.  Accumulation of high-molecular-weight amylose in Alzheimer's disease brains. , 2004, Glycobiology.

[119]  A. Dennison,et al.  Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration , 2004, British Journal of Cancer.

[120]  T. Montine,et al.  Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. , 2004, Chemistry and physics of lipids.

[121]  R. Jope,et al.  The glamour and gloom of glycogen synthase kinase-3. , 2004, Trends in biochemical sciences.

[122]  J. Trojanowski,et al.  Early Vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[123]  Melina R. Uncapher,et al.  Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia , 2003, Neurology.

[124]  Thomas Klockgether,et al.  Nonsteroidal Anti-Inflammatory Drugs and Peroxisome Proliferator-Activated Receptor-γ Agonists Modulate Immunostimulated Processing of Amyloid Precursor Protein through Regulation of β-Secretase , 2003, The Journal of Neuroscience.

[125]  M. Citron,et al.  Anti-Inflammatory Drug Therapy Alters β-Amyloid Processing and Deposition in an Animal Model of Alzheimer's Disease , 2003, The Journal of Neuroscience.

[126]  G. J. Raymond,et al.  Inhibition of Protease-Resistant Prion Protein Accumulation In Vitro by Curcumin , 2003, Journal of Virology.

[127]  S. Barger,et al.  Interleukin-1 Mediates Pathological Effects of Microglia on Tau Phosphorylation and on Synaptophysin Synthesis in Cortical Neurons through a p38-MAPK Pathway , 2003, The Journal of Neuroscience.

[128]  J. Cummings,et al.  A Rationale for Curcuminoids for the Prevention or Treatment of Alzheimers Disease , 2003 .

[129]  G. Barceló-Coblijn,et al.  Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[130]  Takashi Morihara,et al.  Selective inhibition of Aβ42 production by NSAID R‐enantiomers , 2002 .

[131]  N. Nakamichi,et al.  Blockade by ferrous iron of Ca2+ influx through N‐methyl‐d‐aspartate receptor channels in immature cultured rat cortical neurons , 2002, Journal of neurochemistry.

[132]  John D Lambris,et al.  Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[133]  D. Bennett,et al.  Dietary Intake of Antioxidant Nutrients and the Risk of Incident Alzheimer Disease in a Biracial Community Study , 2022 .

[134]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[135]  T. Klockgether,et al.  Noradrenergic Depletion Potentiates β-Amyloid-Induced Cortical Inflammation: Implications for Alzheimer's Disease , 2002, The Journal of Neuroscience.

[136]  G. Morris.  Wolff's Headache and Other Head Pain , 2002 .

[137]  A. Brand,et al.  Docosahexaenoic Acid Abundance in the Brain: A biodevice to Combat Oxidative Stress , 2002, Nutritional neuroscience.

[138]  Xiongwei Zhu,et al.  Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ‘two hit’ hypothesis , 2001, Mechanisms of Ageing and Development.

[139]  J. Overmier,et al.  Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice , 2001, Neurobiology of Aging.

[140]  G. M. Cole,et al.  Phenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology , 2001, Neurobiology of Aging.

[141]  G. Cole,et al.  The Curry Spice Curcumin Reduces Oxidative Damage and Amyloid Pathology in an Alzheimer Transgenic Mouse , 2001, The Journal of Neuroscience.

[142]  D. Dickson,et al.  Analysis of tauopathies with transgenic mice. , 2001, Trends in molecular medicine.

[143]  Hee-Yong Kim,et al.  Mechanisms of action of docosahexaenoic acid in the nervous system , 2001, Lipids.

[144]  D. C. Mitchell,et al.  The role of docosahexaenoic acid containing phospholipids in modulating G protein-coupled signaling pathways , 2001, Journal of Molecular Neuroscience.

[145]  G. Cole,et al.  Church baptizes Joseph and Perry. Eccentric views absolved , 2001, Neurobiology of Aging.

[146]  T. Perlmann,et al.  Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. , 2000, Science.

[147]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[148]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[149]  S. Nishiyama,et al.  Docosahexaenoic acid (DHA) improves the age-related impairment of the coupling mechanism between neuronal activation and functional cerebral blood flow response: a PET study in conscious monkeys , 2000, Brain Research.

[150]  G. Wenk,et al.  Behavioral and ultrastructural changes induced by chronic neuroinflammation in young rats , 2000, Brain Research.

[151]  L. Parnetti,et al.  Cerebrospinal fluid pyruvate levels in Alzheimer’s disease and vascular dementia , 2000, Neurology.

[152]  A. Yang,et al.  Complement Component C1q Modulates the Phagocytosis of Aβ by Microglia , 2000, Experimental Neurology.

[153]  J L Andersson,et al.  Brain regions associated with episodic retrieval in normal aging and Alzheimer’s disease , 1999, Neurology.

[154]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[155]  M. Hossain,et al.  Antioxidative Effects of Docosahexaenoic Acid in the Cerebrum Versus Cerebellum and Brainstem of Aged Hypercholesterolemic Rats , 1999, Journal of neurochemistry.

[156]  B. Halliwell,et al.  F4 ‐ Isoprostanes as Specific Marker of Docosahexaenoic Acid Peroxidation in Alzheimer's Disease , 1999, Journal of neurochemistry.

[157]  T. Tan,et al.  Inhibition of the c-Jun N-terminal kinase (JNK) signaling pathway by curcumin , 1998, Oncogene.

[158]  M. Lynch,et al.  Evidence That Increased Hippocampal Expression of the Cytokine Interleukin-1β Is a Common Trigger for Age- and Stress-Induced Impairments in Long-Term Potentiation , 1998, The Journal of Neuroscience.

[159]  T. Montine,et al.  4‐Hydroxy‐2‐Nonenal Pyrrole Adducts in Human Neurodegenerative Disease , 1997, Journal of neuropathology and experimental neurology.

[160]  M. Mattson,et al.  Secreted form of β‐amyloid precursor protein shifts the frequency dependency for induction of LTD, and enhances LTP in hippocampal slices , 1997, Neuroreport.

[161]  J. Rogers,et al.  Aggregation State‐Dependent Activation of the Classical Complement Pathway by the Amyloid β Peptide , 1997, Journal of neurochemistry.

[162]  L. Lue,et al.  Molecular and Cellular Characterization of the Membrane Attack Complex, C5b-9, in Alzheimer’s Disease , 1997, Neurobiology of Aging.

[163]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[164]  E. Masliah,et al.  Glycogen synthase kinase 3 alteration in Alzheimer disease is related to neurofibrillary tangle formation. , 1996, Molecular and chemical neuropathology.

[165]  M. Beal,et al.  Oxidative damage in Alzheimer's , 1996, Nature.

[166]  Thomas E. Nichols,et al.  Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease , 1996, Neurology.

[167]  J. Price,et al.  Cerebral amyloid deposition and diffuse plaques in ``normal'' aging , 1996, Neurology.

[168]  Thomas E. Nichols,et al.  Alterations in Functional Neuroanatomical Connectivity in Alzheimer's Disease , 1996, Annals of the New York Academy of Sciences.

[169]  L. Parnetti,et al.  INCREASED CSF PYRUVATE LEVELS AS A MARKER OF IMPAIRED ENERGY METABOLISM IN ALZHEIMER'S DISEASE , 1995, Journal of the American Geriatrics Society.

[170]  C. Rao,et al.  Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. , 1995, Cancer research.

[171]  C. Behl,et al.  Hydrogen peroxide mediates amyloid β protein toxicity , 1994, Cell.

[172]  G. Reynolds,et al.  Monoamine neurotransmitters and their metabolites in brain regions in alzheimer's disease: A postmortem study , 1992, Cellular and Molecular Neurobiology.

[173]  G. Cole,et al.  Vitamin E protects nerve cells from amyloid βprotein toxicity , 1992 .

[174]  G. Cole,et al.  Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. , 1992, The American journal of pathology.

[175]  J. Hardy,et al.  Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.

[176]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[177]  A. Conney,et al.  Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. , 1991, Cancer research.

[178]  J. Moossy,et al.  Brain Regional Analysis of NADH‐Cytochrome C Reductase Activity in Alzheimer's Disease , 1990, Journal of neuropathology and experimental neurology.

[179]  R. Katzman.,et al.  Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous neocortical plaques , 1988, Annals of neurology.

[180]  H. Kimura,et al.  [Reduced nicotinamide adenine dinucleotide phosphate diaphorase histochemistry in neocortex and hippocampus in patients with Alzheimer type dementia and aged controls]. , 1987, Rinshō shinkeigaku Clinical neurology.

[181]  R. Sapolsky.  Glucocorticoid toxicity in the hippocampus: reversal by supplementation with brain fuels , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[182]  T. Crow,et al.  Loss of endoplasmic reticulum-associated enzymes in affected brain regions in Huntington's disease and Alzheimer-type dementia , 1985, Journal of the Neurological Sciences.

[183]  L. Butcher,et al.  Alzheimer dementia and reduced nicotinamide adenine dinucleotide (NADH)-diaphorase activity in senile plaques and the basal forebrain , 1985, Neuroscience Letters.

[184]  S. Angaji,et al.  Neuroprotective Effects Of Curcumin , 2011 .

[185]  P. Mcgeer,et al.  Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. , 2010, Journal of Alzheimer's disease : JAD.

[186]  R. Castellani,et al.  Alzheimer disease. , 2010, Disease-a-month : DM.

[187]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[188]  P. Aisen.  The inflammatory hypothesis of Alzheimer disease: dead or alive? , 2008, Alzheimer disease and associated disorders.

[189]  B. Aggarwal,et al.  Curcumin: the Indian solid gold. , 2007, Advances in experimental medicine and biology.

[190]  G. Wolf.  Estimation of the human daily requirement of vitamin E by turnover kinetics of labeled RRR-alpha-tocopherol. , 2007, Nutrition reviews.

[191]  G. Cole,et al.  Phagocytosis and Deposition of Vascular -amyloid in Rat Brains Injected with Alzheimer -amyloid , 2007 .

[192]  S. Rapoport,et al.  n-3 Polyunsaturated fatty acid deprivation in rats decreases frontal cortex BDNF via a p38 MAPK-dependent mechanism , 2007, Molecular Psychiatry.

[193]  Akihiko Takashima,et al.  GSK-3 is essential in the pathogenesis of Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[194]  M. A. Levine,et al.  Determination of Mercury in an Assortment of Dietary Supplements Using an Inexpensive Combustion Atomic Absorption Spectrometry Technique , 2005, Journal of automated methods & management in chemistry.

[195]  Michael T Heneka,et al.  Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. , 2005, Brain : a journal of neurology.

[196]  T. Klockgether,et al.  Nonsteroidal anti-inflammatory drugs repress (cid:1) -secretase gene promoter activity by the activation of PPAR (cid:2) , 2005 .

[197]  L. Baum,et al.  Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. , 2004, Journal of Alzheimer's disease : JAD.

[198]  T. Montine,et al.  Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.

[199]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[200]  Deborah Gustafson,et al.  Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. , 2004, Archives of neurology.

[201]  A. Stoll,et al.  Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. , 2004, The American journal of psychiatry.

[202]  D. Mann,et al.  Glycogen accumulations in the cerebral cortex in Alzheimer's disease , 2004, Acta Neuropathologica.

[203]  T. Montine,et al.  Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. , 2001, The American journal of pathology.

[204]  T. Arendt,et al.  Activities of key glycolytic enzymes in the brains of patients with Alzheimer's disease , 1999, Journal of Neural Transmission.

[205]  B. Hyman,et al.  Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.

[206]  G. Omenn,et al.  Strategy and planning for chemopreventive drug development: Clinical development plans II , 1996, Journal of cellular biochemistry. Supplement.

[207]  Y. Enokido,et al.  [Neuronal apoptosis]. , 1995, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.